Introducing CRG International, Inc.
CRG International, Inc., founded in 1896, has quickly become a global leader in the Life Science Industry, with a strong commitment to innovation, quality, and contributions to environmental protection. With a workforce of over 1,360 employees, under the leadership of CEO John Alison, CRG International, Inc. has established itself as a trusted brand worldwide.
The company develops and produces pharmaceutical drugs across various therapeutic areas, including oncology, immunology, infectious diseases, and neuroscience. It is a leader in in vitro diagnostics (IVD) systems and reagents. Their diagnostics division provides tests and tools for healthcare professionals to detect, diagnose, and monitor various diseases and conditions.
Operating in over 150 countries, with manufacturing facilities, research centers, and sales offices strategically located across North America, Europe, Asia, Middle East and Latin America.
Governance Body
Board of directors in CRG International, Inc.:
- John Alison (CEO)
- Lisa Share (CFO)
- Tim Walter (COO)
These are responsible for defining and implementing the overall risk management framework within CRG International, Inc. They set the strategic direction, policies, and procedures for risk management activities across all lines of defense. They set risk appetite and tolerance levels, approving policies, and procedures, ensuring that proper controls are in place.
As John, Lisa, and Tim aligned on all preceding points, they start to integrate their strategy and delegate transparent to all 3 Line of defense. Let see how the 3 Line of defense is established in CRG pharmaceutical Warehouse department.